Kannan Thanikachalam, MBBS

Kannan Thanikachalam practices at Roswell Park Cancer Institute in Los Angeles, California.

Kannan Thanikachalam's NPI, 1487060489, was assigned on July 10, 2014. Kannan Thanikachalam holds New York license 321116.

Kannan Thanikachalam's primary practice is Roswell Park Cancer Institute, at 344 S Hauser Blvd, Los Angeles, CA 90036 in Los Angeles County. The practice phone is (716) 845-2300.

Kannan Thanikachalam's primary practice is Roswell Park Cancer Institute in Los Angeles, California. Kannan Thanikachalam is also affiliated with Roswell Park Comprehensive Cancer Center. The medical group on file is Roswell Park Comprehensive Cancer Center. Dmand AI also links Kannan Thanikachalam to 1 more hospital, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Kannan Thanikachalam practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Kannan Thanikachalam's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Kannan Thanikachalam is licensed in New York.

CMS data shows 128 Medicare services from Kannan Thanikachalam across 3 procedure codes in 2024, all of them office visits, for 43 Medicare patients. Medicare paid $12,527 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 43 Medicare patients who saw Kannan Thanikachalam in 2024. The largest group is 65 to 74, with 22 patients. 70% of them have high blood pressure, and 67% have high cholesterol. Their average risk score is 2.23, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Kannan Thanikachalam's median patient age at 72, with 40% women.

In 2024, Kannan Thanikachalam wrote 239 Medicare Part D claims for 76 patients. 80% of them were for generic drugs. CMS names the drug for 151 of them, across 7 drugs with 11 or more claims each, at $34,798 in total drug cost. In 2023, CMS named 598 claims across 25 drugs.

Kannan Thanikachalam accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Kannan Thanikachalam as offering telehealth.

Dmand AI links 10 papers to Kannan Thanikachalam, published from 2016 to 2025. 2020 was the busiest year, with 3. Kannan Thanikachalam has published most often in PM R. Kannan Thanikachalam's most frequent co-authors are Jordan M. Cloyd, MD, Ashish Manne, MBBS and Quoc P. Tran, MD.

CMS Open Payments shows 164 general payments to Kannan Thanikachalam from 34 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 90% of the total. Amgen Inc. paid the most, $524.